返回 
加入收藏
瑞舒伐他汀与阿托伐他汀对冠心病患者血脂、动脉粥样硬化程度和血管内皮舒张功能的疗效对比
x
请在关注微信后，向客服人员索取文件
| 篇名： | 瑞舒伐他汀与阿托伐他汀对冠心病患者血脂、动脉粥样硬化程度和血管内皮舒张功能的疗效对比 |
| TITLE： | |
| 摘要： | 目的：对比瑞舒伐他汀与阿托伐他汀对冠心病患者血脂、动脉粥样硬化程度和血管内皮舒张功能的疗效。方法：选择2014年1月－2015年12月于我院心血管内科住院的冠心病患者150例，按照抽签法分为瑞舒伐他汀组（72例）和阿托伐他汀组（78例）。所有患者均调整生活习惯，给予抗血小板和调整血压药物等基础治疗。同时，瑞舒伐他汀组患者给予瑞舒伐他汀钙片10 mg，po，每晚1次；阿托伐他汀组患者给予阿托伐他汀钙片20 mg，po，每晚1次。两组患者均治疗6个月。比较治疗前后两组患者的血脂指标[总胆固醇（TC）、三酰甘油（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）]水平、颈动脉内-中膜厚度（IMT）、颈动脉斑块积分（Crouse积分）、冠状动脉狭窄程度评分（Gensini评分）和肱动脉内径变化百分率（D），记录不良反应发生情况。结果：治疗前，两组患者上述各指标比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者的TC、TG、LDL-C、IMT、Crouse积分和Gensini评分均较治疗前显著下降，HDL-C和D值较治疗前显著上升，且瑞舒伐他汀组患者的TC、TG、LDL-C、Crouse积分和Gensini评分均显著低于阿托伐他汀组，D值显著高于阿托伐他汀组，差异均有统计学意义（P＜0.05）；但两组患者的HDL-C和IMT比较，差异均无统计学意义（P＜0.05）。治疗过程中，瑞舒伐他汀组有1例患者出现头晕，后自行缓解；两组各有4例患者出现转氨酶轻度升高，经护肝治疗后恢复正常。结论：瑞舒伐他汀在降低冠心病患者血脂、改善AS和血管内皮舒张功能方面较阿托伐他汀疗效更显著，且安全性较高。 |
| ABSTRACT： | OBJECTIVE： To compare therapeutic efficacy of rosuvastatin vs. atorvastatin for blood lipid， atherosclerosis and vascular endothelial vasodilation in patients with coronary heart disease （CHD）. METHODS： A total of 150 CHD inpatients selected from cardiovascular medicine department of our hospital during Jan. 2014-Dec. 2015 were divided into rosuvastatin group （72 cases） and atorvastatin group （78 cases） according to lottery method. All patients were adjusted to living habits， given antiplatelet and blood pressure regulating drugs and other basic treatment. At the same time， rosuvastatin group was given Rosuvastatin calcium tablets 10 mg， po， once a night； atorvastatin group was given Atorvastatin calcium tablets 20 mg， po， once a night. Both groups received treatment for 6 months. The levels of blood lipid indexes （TC， TG， HDL-C， LDL-C）， IMT， Crouse scores， Gensini scores and the changes of brachial artery diameter （D） were compared between 2 group before and after treatment. The occurrence of ADR was recorded. RESULTS： Before treatment， there was no statistical significance in above indexes between 2 groups （P＞0.05）. After treatment， the levels of TC， TG， LDL-C， IMT， Crouse scores and Gensini scores in 2 groups were decreased significantly， while the levels of HDL-C and D values were increased significantly， compared to before treatment； the levels of TC， TG， LDL-C， Crouse score and Gensini score in rosuvastatin group were significantly lower than atorvastatin group， and D value was significantly higher atorvastatin group， with statistical significance （P＜0.05）. There was no statistical significance in the levels of HDL-C or IMR between 2 groups （P＜0.05）. During treatment， dizziness occurred in a patient of rosuvastatin group and relieved spontaneously. Four patients in each group had slight elevation of transaminase， and could be reduced to normal after liver protection treatment. CONCLUSIONS： Rosuvastatin shows more significant therapeutic efficacy than that of atorvastatin in reducing blood lipid， improving AS and vascular endothelial vasodilation in CHD patients with good satety. |
| 期刊： | 2017年第28卷第35期 |
| 作者： | 姚立军，陈弹 |
| AUTHORS： | YAO Lijun，CHEN Tan |
| 关键字： | 瑞舒伐他汀；阿托伐他汀；冠心病；血脂；动脉粥样硬化；血管内皮舒张功能 |
| KEYWORDS： | Rosuvastatin； Atorvastatin； Coronary heart disease； Blood lipid； Atherosclerosis； Vascular endothelial vasodilation |
| 阅读数： | 366 次 |
| 本月下载数： | 3 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
